Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Br J Cancer ; 86(9): 1501-9, 2002 May 06.
Article in English | MEDLINE | ID: mdl-11986787

ABSTRACT

Numerous studies demonstrate that the chemopreventive effect of non-steroidal anti-inflammatory drugs on colon cancer is mediated through inhibition of cell growth and induction of apoptosis. For these effects non-steroidal anti-inflammatory drugs have been recently employed as sensitising agents in chemotherapy. We have shown previously that treatments with aspirin and NS-398, a cyclo-oxygenase-2 selective inhibitor, affect proliferation, differentiation and apoptosis of the human colon adenocarcinoma Caco-2 cells. In the present study, we have evaluated the effects of aspirin and NS-398 non-steroidal anti-inflammatory drugs on sensitivity of Caco-2 cells to irinotecan (CPT 11) and etoposide (Vp-16) topoisomerase poisons. We find that aspirin co-treatment is able to prevent anticancer drug-induced toxicity, whereas NS-398 co-treatment poorly affects anticancer drug-induced apoptosis. These effects correlate with the different ability of aspirin and NS-398 to interfere with cell cycle during anticancer drug co-treatment. Furthermore, aspirin treatment is associated with an increase in bcl-2 expression, which persists in the presence of the anticancer drugs. Our data indicate that aspirin, but not NS-398, determines a cell cycle arrest associated with death suppression. This provides a plausible mechanism for the inhibition of apoptosis and increase in survival observed in anticancer drug and aspirin co-treatment.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Apoptosis/drug effects , Aspirin/pharmacology , Enzyme Inhibitors/pharmacology , Nitrobenzenes/pharmacology , Sulfonamides/pharmacology , Topoisomerase Inhibitors , Caco-2 Cells , Camptothecin/analogs & derivatives , Camptothecin/pharmacology , Cell Survival , Etoposide/pharmacology , Humans , Irinotecan
2.
Int Immunol ; 12(6): 787-95, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10837406

ABSTRACT

CD40 is a 50 kDa molecule, a member of the tumor necrosis factor/nerve growth factor receptor family. It is expressed on B cells, monocytes, dendritic cells and various malignant cells. While the critical relevance of this molecule in T cell-dependent B cell activation is already established, the biological role of CD40-CD154 interaction in non-hematopoietic cells is still unknown. Here we show that CD40 is functionally expressed on human melanoma-derived cell lines. No correlation between surface CD40 expression and the origin of the cell line, primary versus metastatic, was observed. Melanoma cells were shown to be able to co-stimulate TCR-triggered human T cells; moreover, because they do not express CD80 or CD86 co-stimulatory structures, the involvement of additional pathways have to be postulated. We have identified CD40 as one of the molecules involved in melanoma cell-mediated co-stimulation of anti-CD3-triggered human CD4(+) T lymphocytes. In addition, a CD40-dependent pathway, able to enhance tumor cell proliferation at low serum concentrations, in vitro, has been shown to be functional in human melanoma cell lines.


Subject(s)
CD40 Antigens/analysis , Melanoma/pathology , T-Lymphocytes/immunology , CD40 Antigens/physiology , CD40 Ligand , Cell Division , Humans , Melanoma/immunology , Membrane Glycoproteins/physiology , Receptors, Antigen, T-Cell/physiology , Tumor Cells, Cultured
3.
J Immunol ; 164(12): 6130-7, 2000 Jun 15.
Article in English | MEDLINE | ID: mdl-10843662

ABSTRACT

It is now well established that NK cells recognize classical and nonclassical MHC class I molecules and that such recognition typically results in the inhibition of target cell lysis. Given the known structural similarities between MHC class I and non-MHC-encoded CD1 molecules, we investigated the possibility that human CD1a, -b, and -c proteins might also function as specific target structures for NK cell receptors. Here we report that expression of CD1a, -b, or -c can partially inhibits target cell lysis by freshly isolated human NK cells and cultured NK lines. The inhibitory effects of CD1 molecules on NK cell could be shown upon expression of individual CD1 proteins in transfected NK-sensitive target cells, and these effects could be reversed by incubation of the target cells with mAbs specific for the expressed form of CD1. Inhibitory effects of CD1 expression on NK-mediated lysis could also be shown for cultured human dendritic cells, which represent a cell type that prominently expresses the various CD1 proteins in vivo. In addition, the bacterial glycolipid Ags known to be bound and presented by CD1 proteins could significantly augment the observed inhibitory effects on target cell lysis by NK cells.


Subject(s)
Antigens, CD1/immunology , Antigens, CD1/metabolism , Cytotoxicity, Immunologic/immunology , Immune Tolerance , Killer Cells, Natural/immunology , Killer Cells, Natural/metabolism , Adjuvants, Immunologic/pharmacology , Antibodies, Monoclonal/pharmacology , Antigens, Bacterial/pharmacology , Antigens, CD1/biosynthesis , Cell Line , Clone Cells , Cytotoxicity Tests, Immunologic , Glycolipids/immunology , HeLa Cells , Histocompatibility Antigens Class I/genetics , Humans , Ligands , Lipids/immunology , Mycobacterium tuberculosis/immunology , Transfection
4.
Eur J Immunol ; 29(12): 4022-9, 1999 12.
Article in English | MEDLINE | ID: mdl-10602012

ABSTRACT

NK cells can recognize and kill tumor as well as certain normal cells. The outcome of the NK-target interaction is determined by a balance of positive and negative signals initiated by different target cell ligands. We have previously shown that human NK cells kill CD40-transfected tumor targets efficiently, but the physiological significance of this is unclear. We now demonstrate that human NK cells can kill dendritic cells (DC), known to express CD40 and other co-stimulatory molecules. The killing was observed with polyclonal NK cells cultured short term in IL-2 as well as with NK cell clones as effectors, and with allogeneic as well as autologous DC as targets. NK cell recognition could be inhibited, but only partially, by preincubation of target cells with monoclonal antibodies against CD40, suggesting that this molecule may be one of several ligands involved. Addition of TNF-alpha of the cultures stimulated the development of a more mature DC phenotype, while addition of IL-10 resulted in a less mature phenotype, with lower expression of CD40 and other co-stimulatory molecules. Nevertheless, such DC were more NK susceptible than the differentiated DC. This may be partly explained by a reduced MHC class I expression observed on such cells, since blocking of MHC class I molecules on differentiated DC or CD94 receptors of NK cells led to increased NK susceptibility. The results show that NK cells may interact with DC, and suggest that the outcome of such interactions depend on the cytokine milieu.


Subject(s)
CD40 Antigens/immunology , Cytotoxicity, Immunologic , Dendritic Cells/immunology , Killer Cells, Natural/immunology , Antigen Presentation , CD40 Antigens/genetics , Gene Transfer Techniques , Histocompatibility Antigens Class I/immunology , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...